Zentalis Pharmaceuticals (NASDAQ:ZNTL) is a biopharmaceutical company focused on discovering and developing small molecule therapeutics aimed at addressing various forms of cancer. Leveraging its proprietary technology platforms, Zentalis is working on a pipeline of oncology compounds with the potential to improve the lives of patients by targeting the molecular and genetic drivers of cancer. The company's objective is to push the boundaries of what is possible in cancer treatment by creating medicines that offer new hope and better outcomes. With a focus on rigorous science and a commitment to innovation, Zentalis Pharmaceuticals strives to bring forward novel therapies that address unmet medical needs in the oncology space.